Bankruptcy Court OKs Correlogic Motion to 'Reject' Quest, LabCorp Pacts
October 07, 2010
Bankruptcy Court OKs Correlogic Motion to 'Reject' Quest, LabCorp Pacts
Correlogic had asked the court to reject agreements it had with Quest and LabCorp as part of its Chapter 11 bankruptcy protection, saying confusion over whether the deals covered Correlogic's ovarian cancer test in its immunoassay format made it challenging for the company to attract investors.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Date, Minimum Bids Set for Sale of Correlogic's Assets
May 27, 2011 / ProteoMonitor - Quest Seeks to Stop Sale of Correlogic's Assets, Claims Rights to OvaCheck IP
April 15, 2011 / ProteoMonitor - LabCorp Licenses Sequella Technology for TB Assay Development
October 22, 2012 / GenomeWeb Daily News - Trovagene Licenses Leukemia Marker to Quest Diagnostics
September 13, 2012 / GenomeWeb Daily News - Quest, Beth Israel, Weill Cornell Collaborate on MDx for Organ Renal Transplant Rejection
March 16, 2012 / GenomeWeb Daily News